

CLINICAL TRIAL NOW ENROLLING

A Phase 0/2 study of **LY3214996** (ERK inhibitor) in combination with **abemaciclib** (CDK4/6 inhibitor) in recurrent glioblastoma participants scheduled for resection to evaluate CNS penetration

PHYSICIAN INFORMATION

Dosing regimen - Phase 0

Abemaciclib = 150mg PO BID x 6 days

LY3214996 = 200mg PO QD x 6 days

Dosing regimen - Phase 2 (21-day cycles)

Abemaciclib = 150mg PO BID x21 days

LY3214996 = 200mg PO QD x21 days


Inclusion Criteria

- Progression following Stupp regimen
- Sufficient archival tissue for eligibility testing:
Tissue must demonstrate:
 - RB+ on IHC or no RB mutations on NGS
 - Chromosomal loss of CDKN2A/B/C or CDK4/6 amp. on array CGH or NGS
 - pERK+ on IHC

Exclusion Criteria

- Retinal diseases such as central or branch retinal artery or venous occlusion
- Prior CDK4/6 or ERK1/2 therapy
- Screening mean QT interval ≥ 470 ms
- History of syncope/arrhythmia

STUDY TIMELINE



PARTNER WITH US

When you refer a patient to the Ivy Center, we will partner with you and your team on a path forward.

To determine your patient's trial eligibility, please call **602.406.8605** or visit **IvyBrainTumorCenter.org**.